Linagliptin Pharmazac: Uses, Dosage & Side Effects
A DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor) for the treatment of type 2 diabetes mellitus in adults, used to improve blood sugar control
Linagliptin Pharmazac is a prescription medication containing linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat type 2 diabetes mellitus in adults. It works by increasing the levels of incretin hormones (GLP-1 and GIP), which stimulate insulin secretion and reduce glucagon release in a glucose-dependent manner, helping to lower blood sugar without causing significant hypoglycemia when used alone. Linagliptin is taken as a single 5 mg tablet once daily, with or without food. A key advantage of linagliptin over other DPP-4 inhibitors is that it does not require dose adjustment in patients with kidney impairment, as it is primarily eliminated through the feces rather than the kidneys.
Quick Facts: Linagliptin Pharmazac
Key Takeaways
- Linagliptin Pharmazac is a once-daily oral DPP-4 inhibitor that lowers blood sugar in adults with type 2 diabetes by enhancing the body's own incretin hormone system, stimulating glucose-dependent insulin release and suppressing inappropriate glucagon secretion.
- Unlike other DPP-4 inhibitors (such as sitagliptin, saxagliptin, and alogliptin), linagliptin does not require dose adjustment for any degree of renal impairment, making it especially suitable for patients with chronic kidney disease or those on dialysis.
- Linagliptin has a low risk of hypoglycemia when used as monotherapy or in combination with metformin, but the risk increases when combined with sulfonylureas or insulin, which may require dose reduction of the companion drug.
- The CARMELINA and CAROLINA cardiovascular outcomes trials demonstrated that linagliptin does not increase the risk of major adverse cardiovascular events (MACE) compared with placebo or the sulfonylurea glimepiride, confirming long-term cardiovascular safety.
- Common side effects are generally mild and include nasopharyngitis (common cold) and cough; rare but serious adverse events include pancreatitis and bullous pemphigoid, which require prompt medical attention.
What Is Linagliptin Pharmazac and What Is It Used For?
Linagliptin Pharmazac contains the active substance linagliptin, which belongs to a class of oral antidiabetic medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors, sometimes referred to as "gliptins." DPP-4 inhibitors represent one of the newer classes of glucose-lowering drugs developed for the management of type 2 diabetes mellitus, a chronic metabolic disease characterized by insulin resistance and progressive decline of beta-cell function in the pancreas. Type 2 diabetes affects over 500 million adults worldwide according to the International Diabetes Federation (IDF), and its prevalence continues to rise, particularly in low- and middle-income countries.
The mechanism of action of linagliptin is closely tied to the incretin system, a physiological pathway that plays a central role in glucose homeostasis. When you eat a meal, specialized cells in the gut release two key incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones account for approximately 50–70% of the insulin secreted after a meal. GLP-1 stimulates insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and promotes satiety. GIP primarily enhances insulin secretion. Crucially, the effects of both GLP-1 and GIP on insulin secretion are glucose-dependent, meaning they stimulate insulin release only when blood glucose is elevated, which provides a built-in safety mechanism against hypoglycemia.
Under normal physiological conditions, the incretin hormones GLP-1 and GIP are rapidly degraded and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), with a half-life of only 1–2 minutes. Linagliptin is a potent, selective, and reversible inhibitor of DPP-4. By blocking this enzyme, linagliptin prevents the breakdown of active GLP-1 and GIP, thereby increasing their circulating concentrations by approximately 2–3 fold. This leads to enhanced glucose-dependent insulin secretion and reduced glucagon levels after meals, resulting in lower blood glucose levels without the risk of hypoglycemia that is associated with insulin secretagogues such as sulfonylureas.
Linagliptin has a unique pharmacokinetic profile among the DPP-4 inhibitors. It binds tightly and in a saturable manner to DPP-4, which serves as its primary binding site in the body. This tight binding results in a very long terminal half-life of over 100 hours. However, the effective half-life relevant to drug accumulation with once-daily dosing is approximately 12 hours. Unlike other DPP-4 inhibitors, linagliptin is primarily eliminated unchanged through the hepatobiliary (fecal) route, with approximately 80% of the administered dose excreted in feces and only about 5% eliminated by the kidneys. This non-renal elimination pathway is the defining pharmacokinetic characteristic of linagliptin and is the reason why no dose adjustment is needed in patients with any degree of renal impairment, including those on dialysis.
Linagliptin Pharmazac is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control in the following settings:
- Monotherapy: When diet and exercise alone do not provide adequate glycemic control and when metformin is inappropriate due to intolerance or contraindications (e.g., significant renal impairment).
- Dual combination therapy: In combination with metformin, when metformin alone with diet and exercise does not provide adequate glycemic control.
- Dual combination therapy: In combination with a sulfonylurea (e.g., glimepiride), when the sulfonylurea alone with diet and exercise does not provide adequate control, and when metformin is inappropriate.
- Triple combination therapy: In combination with metformin and a sulfonylurea, when these agents together with diet and exercise do not provide adequate glycemic control.
- Add-on to insulin: In combination with insulin, with or without metformin, when this regimen alone does not provide adequate glycemic control.
Clinical efficacy of linagliptin has been demonstrated in multiple large randomized controlled trials. In pivotal phase III studies, linagliptin 5 mg once daily as monotherapy reduced HbA1c (glycated hemoglobin, a measure of average blood sugar over 2–3 months) by approximately 0.4–0.7 percentage points compared with placebo, with greater reductions observed in patients with higher baseline HbA1c. When added to metformin, HbA1c reductions of approximately 0.6–0.7 percentage points were observed. These reductions are clinically meaningful, as a 0.5% reduction in HbA1c has been associated with a significant reduction in diabetes-related complications.
DPP-4 inhibitors like linagliptin fill an important niche in diabetes treatment because they provide moderate glucose-lowering efficacy with a low risk of hypoglycemia and no weight gain. They are well-tolerated, require no dose titration, and are taken as a simple once-daily tablet. While newer drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular and renal benefits in certain patient populations, DPP-4 inhibitors remain a valuable option for patients who cannot tolerate or who have contraindications to those agents.
What Should You Know Before Taking Linagliptin Pharmazac?
Contraindications
Linagliptin Pharmazac is contraindicated in patients with known hypersensitivity to the active substance linagliptin or to any of the excipients in the formulation. Serious hypersensitivity reactions, including anaphylaxis, angioedema, and exfoliative skin conditions, have been reported during post-marketing surveillance. If a serious hypersensitivity reaction is suspected, discontinue Linagliptin Pharmazac immediately, assess for other potential causes of the event, and institute alternative treatment for diabetes.
Linagliptin must not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis (DKA). It is not a substitute for insulin in insulin-requiring patients. DPP-4 inhibitors, including linagliptin, are designed to enhance endogenous insulin secretion, which requires functional pancreatic beta cells. In type 1 diabetes, the autoimmune destruction of beta cells means that the incretin-based mechanism cannot function effectively, and insulin therapy is essential.
Warnings and Precautions
Cases of acute pancreatitis have been reported in patients taking DPP-4 inhibitors, including linagliptin. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain that may radiate to the back and may be accompanied by nausea and vomiting. If pancreatitis is suspected, linagliptin should be discontinued immediately and appropriate diagnostic testing performed. Linagliptin should not be restarted if pancreatitis is confirmed.
Before starting treatment with Linagliptin Pharmazac, discuss the following important considerations with your healthcare provider:
- Pancreatitis: Acute pancreatitis, including fatal cases, has been reported with DPP-4 inhibitors. Patients with a history of pancreatitis may be at increased risk. If you experience severe, persistent abdominal pain with or without vomiting, stop taking linagliptin and contact your doctor immediately. The drug should not be restarted after an episode of confirmed pancreatitis.
- Hypoglycemia when combined with sulfonylureas or insulin: When linagliptin is used in combination with a sulfonylurea (such as glimepiride or glibenclamide) or insulin, the risk of hypoglycemia (low blood sugar) is increased. Your doctor may consider reducing the dose of the sulfonylurea or insulin when initiating combination therapy with linagliptin. Learn to recognize the symptoms of hypoglycemia: sweating, trembling, fast heartbeat, hunger, dizziness, confusion, and blurred vision.
- Heart failure: Data from the SAVOR-TIMI 53 trial with saxagliptin (another DPP-4 inhibitor) raised concerns about a possible increased risk of hospitalization for heart failure with DPP-4 inhibitors. However, the CARMELINA trial specifically evaluated linagliptin and found no increased risk of hospitalization for heart failure compared with placebo. Despite this reassurance, patients with known heart failure should be monitored, and the risk-benefit assessment should be considered.
- Bullous pemphigoid: Cases of bullous pemphigoid (a skin condition causing large, fluid-filled blisters) have been reported with DPP-4 inhibitors, including linagliptin. If bullous pemphigoid is suspected, linagliptin should be discontinued and referral to a dermatologist considered for diagnosis and treatment.
- Hepatic impairment: Clinical experience in patients with severe hepatic impairment is limited. Linagliptin should be used with caution in these patients.
Pregnancy and Breastfeeding
There are no adequate and well-controlled studies of linagliptin in pregnant women. Animal reproduction studies did not reveal any evidence of teratogenicity at doses up to approximately 49 times the maximum recommended human dose. However, as a precautionary measure, linagliptin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment. If you become pregnant while taking linagliptin, contact your doctor immediately to discuss alternative diabetes management options. Insulin is generally considered the preferred antidiabetic treatment during pregnancy.
It is not known whether linagliptin is excreted in human breast milk. Animal studies have shown excretion of linagliptin in milk. A risk to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue linagliptin therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. Discuss this decision carefully with your healthcare provider.
Children and Adolescents
The safety and efficacy of linagliptin in children and adolescents below 18 years of age have not been established. No data are available. Therefore, Linagliptin Pharmazac is not recommended for use in the pediatric population. Type 2 diabetes in children and adolescents, while increasing in prevalence, requires age-appropriate treatment strategies that have been specifically studied and validated in this population.
Driving and Operating Machinery
Linagliptin has no or negligible influence on the ability to drive and use machines when used alone or in combination with agents that do not cause hypoglycemia (such as metformin). However, when linagliptin is combined with a sulfonylurea or insulin, patients should be warned about the risk of hypoglycemia, which can impair the ability to drive and operate machinery. If you experience symptoms of hypoglycemia while driving, pull over safely and treat the hypoglycemia before resuming driving.
How Does Linagliptin Pharmazac Interact with Other Drugs?
Linagliptin has a relatively favorable drug interaction profile compared with many other antidiabetic medications. It is a weak competitive inhibitor and a weak mechanism-based inhibitor of CYP3A4, but it does not inhibit or induce other CYP enzymes at clinically relevant concentrations. Linagliptin is a substrate of the efflux transporter P-glycoprotein (P-gp) and of CYP3A4, and to a lesser extent CYP2D6. These characteristics inform the known drug interaction profile.
In clinical pharmacology studies and population pharmacokinetic analyses, the following interactions have been evaluated:
Clinically Relevant Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Rifampicin | Reduced linagliptin exposure by ~40% (strong P-gp/CYP3A4 inducer); may reduce DPP-4 inhibition below therapeutic levels | Combination not recommended; efficacy may be reduced. Consider alternative antidiabetic or antimycobacterial agents |
| Sulfonylureas (e.g., glimepiride, glibenclamide) | No pharmacokinetic interaction, but pharmacodynamic additive glucose-lowering effect increases hypoglycemia risk | Consider reducing sulfonylurea dose when initiating linagliptin combination |
| Insulin | No pharmacokinetic interaction, but additive glucose-lowering effect increases hypoglycemia risk | Consider reducing insulin dose when adding linagliptin; monitor blood glucose closely |
| Ritonavir | Increased linagliptin exposure by ~2-fold (strong P-gp/CYP3A4 inhibitor) | No dose adjustment needed; increase is not considered clinically significant due to saturable DPP-4 binding |
| Metformin | No clinically relevant pharmacokinetic interaction in either direction | No dose adjustment needed for either drug |
| Pioglitazone | No clinically relevant pharmacokinetic interaction | No dose adjustment needed |
| Warfarin | No clinically relevant effect on warfarin pharmacokinetics or anticoagulant activity (INR) | No dose adjustment needed |
| Digoxin | No clinically relevant pharmacokinetic interaction | No dose adjustment needed |
| Simvastatin | No clinically relevant effect on simvastatin pharmacokinetics | No dose adjustment needed |
| Oral contraceptives | No clinically relevant effect on ethinylestradiol or levonorgestrel pharmacokinetics | No dose adjustment needed |
The interaction with rifampicin is the most clinically significant. Rifampicin is a potent inducer of P-glycoprotein and CYP3A4, and co-administration with linagliptin resulted in a 39.6% decrease in linagliptin steady-state AUC (area under the curve) and a 43.8% decrease in peak plasma concentration (Cmax). This level of reduction is predicted to result in subtherapeutic DPP-4 inhibition, particularly in the trough period between doses. Other strong P-gp/CYP3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, and St. John's Wort) are expected to produce similar reductions and should also be used with caution.
In contrast, ritonavir (a strong P-gp and CYP3A4 inhibitor) increased linagliptin exposure approximately 2-fold. However, this increase is not considered clinically significant because linagliptin's binding to DPP-4 is saturable, meaning that the additional circulating drug does not proportionally increase the pharmacological effect. For this reason, no dose adjustment is recommended when linagliptin is co-administered with strong CYP3A4/P-gp inhibitors, including ritonavir, ketoconazole, and itraconazole.
Always inform your doctor and pharmacist about all medications you are taking, including prescription and over-the-counter drugs, vitamins, and herbal supplements (particularly St. John's Wort). While linagliptin has few clinically significant drug interactions, maintaining a comprehensive medication list helps ensure your safety and allows optimal management of your diabetes and any other conditions.
What Is the Correct Dosage of Linagliptin Pharmazac?
Linagliptin Pharmazac is available as a 5 mg film-coated tablet for oral administration. The dosing regimen is straightforward: one tablet once daily. This simplicity is a notable advantage in diabetes management, as adherence to medication regimens is a critical factor in achieving optimal glycemic control. Studies have consistently shown that simpler dosing regimens are associated with better adherence and improved clinical outcomes in patients with chronic diseases such as type 2 diabetes.
Adults
Standard Adult Dose
5 mg once daily, taken at any time of the day, with or without food. Swallow the tablet whole with water. Try to take it at approximately the same time each day to help establish a routine. If a dose is missed, take it as soon as you remember on the same day. Do not take a double dose on the same day.
| Therapy Type | Linagliptin Dose | Companion Drug Adjustment |
|---|---|---|
| Monotherapy | 5 mg once daily | Not applicable |
| + Metformin | 5 mg once daily | Continue metformin at current dose |
| + Sulfonylurea | 5 mg once daily | Consider reducing sulfonylurea dose to lower hypoglycemia risk |
| + Insulin (± metformin) | 5 mg once daily | Consider reducing insulin dose to lower hypoglycemia risk |
Children and Adolescents
Linagliptin Pharmazac is not recommended for use in patients under 18 years of age. Safety and efficacy have not been established in the pediatric population. Type 2 diabetes in children and adolescents is an emerging clinical challenge, and treatment decisions should be guided by age-appropriate evidence. Metformin and insulin are the primary treatment options approved for pediatric use in most countries.
Elderly Patients
No dose adjustment is required for elderly patients. In clinical trials, patients aged 65 and older, including those over 75, showed similar safety and efficacy profiles to younger adults. However, greater sensitivity of some older individuals cannot be ruled out, and healthcare providers should monitor elderly patients for any signs of adverse effects, particularly when linagliptin is combined with insulin or sulfonylureas that carry a higher risk of hypoglycemia.
Renal Impairment
No dose adjustment is required for patients with any degree of renal impairment. This is a clinically important advantage of linagliptin, as many patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In the CARMELINA trial, which enrolled a high proportion of patients with CKD, linagliptin demonstrated a comparable safety and efficacy profile regardless of renal function. Because linagliptin is primarily eliminated through non-renal pathways (approximately 80% via feces, only 5% via kidneys), its pharmacokinetics are not significantly affected by reduced kidney function. Other DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, vildagliptin) all require dose reduction in moderate to severe renal impairment.
Hepatic Impairment
Based on pharmacokinetic studies, no dose adjustment is necessary for patients with mild, moderate, or severe hepatic impairment. Exposure to linagliptin was not meaningfully altered in subjects with hepatic impairment. However, clinical experience in patients with severe hepatic impairment is limited, and caution is advised in these patients.
Missed Dose
If you forget to take a dose, take it as soon as you remember on the same day. If it is already time for your next dose, skip the missed dose entirely and take the next dose at your regular scheduled time. Never take two doses on the same day to make up for a missed dose. If you frequently forget to take your medication, consider using a pill organizer, setting a daily alarm, or linking your dose to a consistent daily activity such as brushing your teeth.
Overdose
During clinical trials, single doses of up to 600 mg of linagliptin (120 times the recommended dose) were administered to healthy volunteers and were generally well tolerated. There is no experience with doses above 600 mg. In the event of an overdose, standard supportive measures should be employed, such as removing unabsorbed drug from the gastrointestinal tract, clinical monitoring, and instituting supportive treatment as dictated by the patient's clinical status. Linagliptin is not meaningfully removed by hemodialysis (only approximately 5% removed over 4 hours) due to its extensive protein and tissue binding.
One of the most important clinical advantages of linagliptin is that the same 5 mg dose is used regardless of kidney function. Approximately 40% of patients with type 2 diabetes develop some degree of chronic kidney disease, and many oral antidiabetic drugs require dose adjustment or are contraindicated in CKD. Linagliptin's unique non-renal elimination pathway simplifies prescribing in this common clinical scenario.
What Are the Side Effects of Linagliptin Pharmazac?
Like all medicines, Linagliptin Pharmazac can cause side effects, although not everybody gets them. The safety profile of linagliptin has been extensively studied in clinical trials involving more than 14,000 patients and has been well characterized through years of post-marketing surveillance. One of the key attributes of linagliptin is its overall favorable tolerability, with an adverse event profile generally comparable to placebo when used as monotherapy or in combination with metformin.
The CARMELINA cardiovascular outcomes trial (6,979 patients followed for a median of 2.2 years) and the CAROLINA active-comparator trial (6,033 patients followed for a median of 6.3 years, comparing linagliptin with glimepiride) provided extensive long-term safety data. These trials confirmed that linagliptin does not increase the risk of major adverse cardiovascular events, heart failure hospitalization, or overall mortality compared with placebo or glimepiride.
Common
May affect up to 1 in 10 people
- Hypoglycemia (when used with sulfonylurea or insulin)
- Nasopharyngitis (common cold, runny or stuffy nose, sore throat)
- Cough
- Diarrhea (when used with metformin)
Uncommon
May affect up to 1 in 100 people
- Pancreatitis (inflammation of the pancreas – severe abdominal pain radiating to the back)
- Hypersensitivity reactions (rash, urticaria/hives)
- Mouth ulceration (oral ulceration, stomatitis)
- Elevated lipase levels (blood test finding, usually without symptoms)
Rare
May affect up to 1 in 1,000 people
- Bullous pemphigoid (large, fluid-filled blisters on the skin, often with itching)
- Angioedema (swelling of the face, lips, tongue, or throat)
- Anaphylaxis (severe, life-threatening allergic reaction)
- Exfoliative skin conditions (severe rash with skin peeling)
Not Known
Frequency cannot be estimated from available data
- Rhabdomyolysis (breakdown of muscle tissue – muscle pain, weakness, dark urine)
Understanding Key Side Effects
Hypoglycemia: When linagliptin is used alone or in combination with metformin, the incidence of hypoglycemia is very low (similar to placebo) because its glucose-lowering action is glucose-dependent. However, when combined with sulfonylureas or insulin, which stimulate insulin release regardless of blood glucose levels, the risk of hypoglycemia increases significantly. In the CAROLINA trial comparing linagliptin with glimepiride (a sulfonylurea), hypoglycemia occurred in 10.6% of linagliptin-treated patients versus 37.7% of glimepiride-treated patients, demonstrating a substantially lower hypoglycemia risk with linagliptin.
Pancreatitis: Acute pancreatitis has been reported in patients taking DPP-4 inhibitors, including linagliptin. In the CARMELINA trial, the incidence of adjudicated acute pancreatitis was 0.3% in the linagliptin group versus 0.1% in the placebo group. While the absolute risk is low, patients should be aware of the symptoms: sudden, severe abdominal pain that often radiates to the back, usually accompanied by nausea and vomiting. If pancreatitis is suspected, stop the medication immediately and seek emergency medical care.
Bullous pemphigoid: This is a rare but serious dermatological adverse effect that has been associated with DPP-4 inhibitors as a class. It typically presents as tense, fluid-filled blisters on the skin, often preceded by intense itching or an eczema-like rash. The onset can be months to years after starting therapy. If bullous pemphigoid is suspected or diagnosed, linagliptin should be discontinued and the patient referred to a dermatologist. Most cases resolve after stopping the DPP-4 inhibitor, although additional treatment with topical or systemic corticosteroids may be needed.
Weight effects: Linagliptin is considered weight-neutral. In clinical trials, linagliptin did not cause significant weight gain or weight loss compared with placebo. This is an advantage over sulfonylureas (which typically cause weight gain of 1–3 kg) and insulin (which can cause more substantial weight gain), and is an important consideration for patients with type 2 diabetes, many of whom are overweight or obese.
Stop taking Linagliptin Pharmazac and seek emergency medical care if you experience: severe abdominal pain that may radiate to the back (possible pancreatitis); swelling of the face, lips, tongue, or throat with difficulty breathing (angioedema); large, fluid-filled skin blisters (bullous pemphigoid); or signs of a severe allergic reaction such as widespread rash, hives, or difficulty breathing.
How Should You Store Linagliptin Pharmazac?
Proper storage of medications is essential to maintain their effectiveness and safety throughout their shelf life. Linagliptin Pharmazac should be stored at room temperature, not exceeding 25°C (77°F). There is no need for refrigeration. The tablets should be kept in their original packaging (blister pack within the carton) to protect them from moisture and light, as linagliptin can be sensitive to humidity.
Do not remove tablets from the blister pack until you are ready to take them. Keep the medication out of the sight and reach of children. Do not use the medication after the expiry date stated on the blister and carton. The expiry date refers to the last day of the stated month.
Do not dispose of medications via wastewater or household waste. Ask your pharmacist about the appropriate way to dispose of medications that are no longer needed. Many pharmacies and local authorities offer medication take-back programs. Proper disposal helps to protect the environment and prevents accidental ingestion by children, pets, or others.
If the tablets appear damaged, discolored, or show signs of deterioration (such as crumbling or unusual odor), do not take them and consult your pharmacist for replacement. Always check the expiry date before taking each tablet.
What Does Linagliptin Pharmazac Contain?
Understanding the composition of your medication is important, particularly if you have known allergies or intolerances to specific substances. Each Linagliptin Pharmazac 5 mg film-coated tablet contains the following:
Active Substance
Each tablet contains 5 mg of linagliptin. Linagliptin is a xanthine-based molecule with the chemical name (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-1H-purine-2,6-dione. It has a molecular weight of 472.54 g/mol.
Excipients (Inactive Ingredients)
The tablet core contains:
- Mannitol – a sugar alcohol used as a tablet filler and diluent
- Pregelatinized starch – a binding agent that helps hold the tablet together
- Maize starch (corn starch) – a disintegrant that helps the tablet break down in the stomach
- Copovidone – a polymer used as a binder
- Magnesium stearate – a lubricant that prevents the tablet from sticking to manufacturing equipment
The film coating contains:
- Hypromellose (hydroxypropyl methylcellulose) – forms the film coat
- Titanium dioxide (E171) – a white pigment
- Talc – a glidant and anti-adherent
- Macrogol (polyethylene glycol) – a plasticizer for the coating
- Iron oxide red (E172) – a coloring agent giving the tablet its light pink appearance
The tablets are light pink, round, and biconvex in shape. They may bear debossing marks for identification purposes. Linagliptin Pharmazac tablets do not contain lactose, gluten, or gelatin. If you have known allergies to any of the listed excipients, inform your healthcare provider before starting treatment.
Frequently Asked Questions About Linagliptin Pharmazac
Linagliptin Pharmazac is used to treat type 2 diabetes mellitus in adults. It contains the active ingredient linagliptin, a DPP-4 inhibitor that helps lower blood sugar levels by enhancing the body's natural incretin hormone system. It can be used alone (when metformin is not suitable) or in combination with other diabetes medications including metformin, sulfonylureas, thiazolidinediones, or insulin. It is not for type 1 diabetes or diabetic ketoacidosis.
The key difference is its unique pharmacokinetic profile. Linagliptin is the only DPP-4 inhibitor that is primarily eliminated through the feces (approximately 80%) rather than the kidneys. This means no dose adjustment is needed for patients with any degree of kidney impairment, including those on dialysis. Other DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, vildagliptin) all require dose reductions in moderate to severe renal impairment. Additionally, the CARMELINA and CAROLINA cardiovascular outcomes trials provided robust evidence of cardiovascular safety for linagliptin.
No. Linagliptin is considered a weight-neutral medication. In clinical trials, it did not cause significant weight gain or weight loss compared with placebo. This is an advantage over some other diabetes medications such as sulfonylureas and insulin, which often lead to weight gain. For patients with type 2 diabetes who are concerned about weight management, linagliptin offers effective blood sugar control without the added burden of weight gain.
Yes. Linagliptin Pharmazac can be taken with or without food, at any time of the day. Food does not significantly affect the absorption or efficacy of linagliptin. However, it is recommended to take it at approximately the same time each day to help maintain consistent blood levels and to make it easier to remember your daily dose.
Yes, based on currently available evidence. Linagliptin has been studied in two large cardiovascular outcomes trials. The CARMELINA trial (6,979 patients, median follow-up 2.2 years) demonstrated non-inferiority to placebo for major adverse cardiovascular events (MACE), meaning it did not increase heart attack, stroke, or cardiovascular death risk. Importantly, it also did not increase the risk of hospitalization for heart failure. The CAROLINA trial (6,033 patients, median follow-up 6.3 years) compared linagliptin directly with the sulfonylurea glimepiride and showed non-inferior cardiovascular outcomes, with significantly less hypoglycemia in the linagliptin group.
If you miss a dose, take it as soon as you remember on the same day. If it is already close to the time for your next scheduled dose, skip the missed dose and take the next one at the usual time. Never take two tablets on the same day to compensate for a missed dose. If you are unsure what to do, contact your doctor or pharmacist for guidance.
References
- European Medicines Agency (EMA). Trajenta (linagliptin) – Summary of Product Characteristics. Last updated 2025. Available from: EMA – Trajenta.
- U.S. Food and Drug Administration (FDA). Tradjenta (linagliptin) tablets – Prescribing Information. Revised 2024. Available from: FDA – Tradjenta Label.
- Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. doi:10.1001/jama.2018.18269.
- Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155–1166. doi:10.1001/jama.2019.13772.
- American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1–S352.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi:10.1007/s00125-022-05787-2.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642–653. doi:10.1038/s41574-020-0399-8.
- British National Formulary (BNF). Linagliptin. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Endocrinology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following EMA, FDA, ADA, and EASD guidelines
Evidence Standard
Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials (CARMELINA, CAROLINA)
Accessibility
WCAG 2.2 Level AAA – Reviewed for screen readers, keyboard navigation, and assistive technology compatibility
This article was written by medical specialists and reviewed by an independent medical board. All medical claims are supported by peer-reviewed evidence and international clinical guidelines. This content has no commercial funding and is free from pharmaceutical industry influence. Last reviewed: .